Organisation paid for research Program year 2025 Source: CMS Open Payments

The Center for Pharmaceutical Research

Neither a doctor nor a teaching hospital

Research payments

$2,063,352

116 payments

Through program year 2025, The Center for Pharmaceutical Research is reported as receiving $2,063,352 in research payments, across 116 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $41,175 1
2024 Research $8,973 2
2023 Research $328,204 9
2022 Research $963,036 11
2021 Research $69,810 5
2020 Research $384,298 29
2019 Research $267,855 59

Breakdown

Who paid Research payments · program years 2019–2025
  1. Emergent BioSolutions Inc. $1,538,894 47 payments
  2. Regeneron Pharmaceuticals, Inc. $183,338 30 payments
  3. Eisai Inc. $139,583 22 payments
  4. Flexion Therapeutics, Inc. $69,190 1 payment
  5. Novartis Pharmaceuticals Corporation $43,454 2 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $31,079 1 payment
  7. Avanir Pharmaceuticals, Inc. $18,054 4 payments
  8. Mitsubishi Tanabe Pharma Development America, Inc. $13,912 2 payments
  9. AstraZeneca AB $13,266 2 payments
  10. Moderna TX, Inc. $6,695 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 $328,204 9 payments
  2. A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0328 $197,467 1 payment
  3. A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0327 $182,505 1 payment
  4. A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0329 $161,741 1 payment
  5. Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults $135,121 8 payments
  6. A Phase 3 Randomized, Double-Blind, Multi-Dose, Placebo and Naproxen-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Pain Due to Osteoarthritis of the Knee Or Hip $132,316 21 payments
  7. A 52 Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Belviq XR??in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years $124,786 11 payments
  8. A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0325 $107,060 1 payment
  9. A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0332 $89,074 1 payment
  10. A Phase 2 Parallel-Group, Randomized, Double-Blind Study to Assess the Safety and Immunogenicity of PXVX0317 (Chikungunya Virus Virus-Like Particle Vaccine [CHIKV-VLP], unadjuvanted or alum-adjuvanted) $82,893 8 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record